Triple-negative breast cancer (TNBC) is characterized by the loss of expression of the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) [1,2,3,4]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.